C5a Protein, Human, Recombinant

1/2
Price:
Size:
Number:

C5a Protein, Human, Recombinant: Product Information

Purity
> 94 % as determined by SDS-PAGE
Endotoxin
Please contact us for more information.
Activity
Measured by its ability to induce N-acetyl-β-D-glucosaminidase release from differentiated U937 human histiocytic lymphoma cells. The ED50 for this effect is typically 5-15 ng/ml.
Protein Construction
A DNA sequence encoding the active form of human C5a (Leu 679-Arg 751) was expressed.
Accession#
Expressed Host
E. coli
Species
Human
Predicted N Terminal
Based on N-terminal sequencing analysis, the first 7 aa of C5a is: MLQKKIE
Molecule Mass
The recombinant human C5a consists of 74 amino acids and has a predicted molecular mass of 8.3 kDa which is also estimated by SDS-PAGE.
Formulation
Lyophilized from sterile PBS, pH 7.4
1. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
2. Please contact us for any concerns or special requirements.
Please refer to the specific buffer information in the hard copy of CoA.
Shipping
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability & Storage
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

C5a Protein, Human, Recombinant: Images

Measured by its ability to induce N-acetyl-β-D-glucosaminidase release from differentiated U937 human histiocytic lymphoma cells. The ED50 for this effect is typically 5-15 ng/ml.

C5a Protein, Human, Recombinant: Alternative Names

C5a Protein, Human; C5b Protein, Human; C5D Protein, Human; C5Da Protein, Human; Complement 5a Protein, Human; CPAMD4 Protein, Human; ECLZB Protein, Human

C5a Background Information

C5a is a protein fragment released from complement component C5. This 74 amino acid peptide in humans is generated by the cleavage of C5a convertase on the C5 α-chain during the classical, alternative, and lectin pathways of complement activation. The structure of C5a includes a core region consisting of four, anti-parallel alpha-helices held together by three disulfide linkages and a structured C-terminal tail, and C5a is rapidly metabolised by carboxypeptidase B to a 73 amino acid low activity form, C5a des-Arg. C5a is an extremely potent proinflammatory mediator, as well as a potent chemotactic factor for neutrophils and other leukocytes. It causes histamine release, increases in vascular permeability, induces several cytokines production from leukocytes, enhances neutrophil-endothelial cell adhesion, and augments the humoral and cell-mediated immune response. C5a is quickly metabolised by carboxypeptidases, forming the less potent C5adesArg. Acting via a classical G protein-coupled receptor, CD88, C5a and C5adesArg exert a number of effects essential to the innate immune response, while their actions at the more recently discovered non-G protein-coupled receptor, C5L2 (or GPR77), remain unclear. The widespread expression of C5a receptors throughout the body allows C5a to elicit a broad range of effects. Thus, C5a has been found to be a significant pathogenic driver in a number of immuno-inflammatory diseases, making C5a inhibition an attractive therapeutic strategy. C5a is a strong chemoattractant and is involved in the recruitment of inflammatory cells such as neutrophils, eosinophils, monocytes, and T lymphocytes, in activation of phagocytic cells and release of granule-based enzymes and generation of oxidants, all of which may contribute to innate immune functions or tissue damage. Accordingly, the anaphylatoxin C5a is implicated in a variety of diseases such as rheumatoid arthritis, systemic lupus erythematosus, reperfusion injury, Alzheimer's disease, and sepsis.
Full Name
complement component 5
References
  • Guo RF, et al.. (2005) Role of C5a in inflammatory responses. Annu Rev Immunol. 23: 821-52.
  • Guo RF, et al. (2006) C5a, a therapeutic target in sepsis. Recent Pat Antiinfect Drug Discov. 1(1): 57-65.
  • Manthey HD, et al. (2009) Complement component 5a (C5a). Int J Biochem Cell Biol. 41(11): 2114-7.
  • Inflammatory responses induced by lipopolysaccharide are amplified in primary human monocytes but suppressed in macrophages by complement protein C5a
    Author
    V Seow, J Lim, A Iyer, JY Suen, JK Ariffin…
    Year
    2013
    Journal
    The Journal of Immunology
  • Receptor residence time trumps drug-likeness and oral bioavailability in determining efficacy of complement C5a antagonists
    Author
    Seow, V;Lim, J;Cotterell, AJ;Yau, MK;Xu, W;Lohman, RJ;Kok, WM;Stoermer, MJ;Sweet, MJ;Reid, RC;Suen, JY;Fairlie, DP;
    Year
    2016
    Journal
    Sci Rep
    Application
    cell-based
  • Partial ligand-receptor engagement yields functional bias at the human complement receptor, C5aR1
    Author
    Pandey, S;Li, X;Srivastava, A;Baidya, M;Kumari, P;
    Year
    2019
    Journal
    bioRxiv
    Application
    cell-based
Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait